One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...
KEY TAKEAWAYS Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage ...
Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...
Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight ...
Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...
Novo Nordisk A/S rose the most in a month after an experimental shot delivered as much as 22% weight loss in an early-stage ...
Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.
1don MSN
The actor said he lost 40 pounds taking GLP-1 medication before a negative side effect necessitated a change to a different ...
Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...
Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly ...
On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback